drugset / Trial / NCT01947738
Safety Study of VBY-891 in Healthy Volunteers After Single or Multiple (7 Days) of Oral Dosing (VBY891P1)
RandomizedParallel-groupTriple-blindTreatment
Summary
Psoriasis is an inflammatory autoimmune disease that might be controlled by a cathepsin S inhibitor like VBY-891.
Timeline
- Start
- 2013-03
- Primary completion
- 2013-05
- Completion
- 2013-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VBY-891 | Unknown | — | Oral |
Indications
No indication recorded.